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 INTRODUCTION 
Schizophrenia is a variable, significant and disruptive psychopathology, 
affecting every aspect of human life experiences like perception, cognition, 
emotion and behaviour, resulting in profound and often long lasting 
impairment, not only for persons affected, but also for the family and society, 
causing huge consumption of health costs, distress, loss of manpower, quality 
of life and productivity and ‘arguably the worst disease affecting mankind, 
even AIDS not exempted’ [Nature 1988]. 
It has puzzled physicians, philosophers and general public alike for 
centuries, as if it is a single disease, but it is probably comprises a group of 
syndromes due to multifactorial aetiology involving genetic, developmental, 
psychoneuroimmunological  and environmental interactions in manifesting the 
disease. 
Schizophrenia affects approximately 1% of the population, involving all 
cultures, society, race and nations, and commonly affecting during the fertile 
period of adolescent and young adulthood with a tendency for chronic course. 
The treatment of schizophrenia has evolved over a long period of history 
with ancient remedies of plant extracts,with the revolutionary introduction of 
chlorpromazine in the 1950’s and the beginning of research on 
psychopharmacology. Based on the clinical improvement of psychotic 
symptoms and molecular studies of neurotransmitters and receptors,the 
dopaminergic hypothesis of schizophrenia was proposed for these early 
indroduction of psychotropic drugs, following the indroduction of  
chlorpromazine, preferentially blocking dopamine 2 receptors, hence these 
drugs were called dopamine antagonists or typical or first generations 
antipsychotics. 
Apart from the effectiveness, it caused movement disorders of both 
acute and chronic [Tardive dyskinesias] in addition to other side effects, 
prompting research for drugs with minimum side effect profile resulting in the 
introduction of Dopamine-serotonin antagonists or atypical or second 
generation [preferentially blocking serotonin receptors] antipsychotics with 
different  side effect profiles and equal efficacy except clozapine  with much 
enthusiasm.   [Canadian journal of psychiatry 2005;50;703-14.] 
Although they were associated with less incidence of dyskinesias, soon 
it was found that they cause various derangements in metabolic parameters like 
weight gain, hypertension, dyslipidemia and dysregulation of glucose 
metabolism, which are established risk factors for cardiac and cerebrovascular 
complications, which causes catastrophic implications and premature death, 
requiring long term prophylaxis, dispelling the myth of superiority of atypicals 
over the typical antipsychotics.   [schizophrenia Research 2004;71;195-212]. 
So the rational of the study is to find out the emergence of metabolic 
syndrome, which was established in various studies in the past, of the second 
generation antipsychotics and comparing it against first generation 
antipsychotics, in individuals with drug naïve first episode of schizophrenia to 
avoid the disease effect, in our Institute of mental health, Madras Medical 
College, Chennai-10.                       
REVIEW OF LITERATURE 
METABOLIC SYNDROME 
It is, relatively a new concept involving multiple systems resulting in 
long lasting morbidity and mortality. It can be defined as a constellation of 
lipid and non-lipid risk factors of metabolic origin, closely related to each other 
via insulin resistance. It includes obesity, atherogenic dyslipidemia, elevated 
blood pressure [with or without glucose intolerance], prothrombotic and  
proinflammatory states.  [Pi sunyer FX ;Metabolic syndrome. Med clinic 
North America 2007’ 91;1020-40].            
PATHOGENESIS 
The pathogenesis of metabolic syndrome is complex and the interactions 
between the individual components are poorly understood as 1.Complex 
interaction between visceral adipose tissue and insulin resistance is widely 
accepted 2.Visceral obesity is atherogenic due to lipolysis and release non-
esterified free fatty acids.3.Increased hepatic and plasma free fatty acids causes 
glucose dysregulation and vasoconstriction resulting in elevated blood 
pressure.4.Other by-products of lipolysis like pro-inflammatory markers, 
damaging vascular system include angiotensinogen, adipsin, adiponectin, 
leptin, interleukin-6, and tumour necrosis factor- [Fernandez Real and Ricart 
2003, Sutherland et al 2004, Weisberg et al 2003]. According toMc envoy, in 
psychiatric populations, the clinical antipsychotic trial of intervention 
effectiveness schizophrenia trial [CATIE] shows 40.9 percent [male-36, 
female-51.6]. And in bipolar affective disorder it is 30 percent using the NCEP-
ATP III criteria-  Fagiolini et al. 2005.  Schizophrenia has 2.5 times higher risk 
of cardio and cerebrovascular deaths- [Arch Gen Psychiatry 2007;64’242-49].  
PHARMACOLOGICAL MANAGEMENT OF SCHIZOPHRENIA 
Apart from the psychosocial management of schizophrenia as a part of 
the holistic approach, Current evidence based pharmacotherapeutics play an 
important role and it can be broadly divided in to two groups based on the 
structures and clinical profile. 
FIRST GENERATION ANTIPSYCHOTICS. 
They represent the first group of effective agents introduced in the 
1950’s and thereafter, with dopamine -2 receptor antagonism, causing acute 
and chronic neurological side effects at their clinically effective doses. 
clinically it can be divided in to low potency drugs [phenothiazines] having 
significant alpha blocking and ant cholinergic actions and less propensity to 
cause EPS, and middle and high potency with less alpha blocking, 
anticholinergic  and sedation. Eg. Haloperidol, a potent buterophenone 
derivative, is the representative drug with a potent D2 blocker with minimal 
anticholinergic and autonomic effects prone to increased occurrence of 
neurological [movement disorders] side effects. 
SECOND GENERATION ANTIPSYCHOTICS. 
These came in to clinical use in the 1970’s with low affinity for 
dopamine 2 receptor, greater affinities for serotonin 1A, 2A, 2C, 367 nor-
epinephrine and histamine receptors with less neurological side effects, but 
greater propensity for metabolic side effects, called atypical/serotonin-
dopamine antagonist without superior efficacy than typical or with limited edge 
except clozapine. Risperidone is one of the commonly used drugs in Indian 
settings, which has potent antagonism at D2 receptor, 5HT-2A and also high 
affinity for Alfa -1 and 2, H1 receptor with moderate affinity for5HT-1C, 1D, 
5HT-2A and weak affinity for D1 receptor with no affinity for adrenergic and 
cholinergic receptors.  
ANTIPSYCHOTICS – EQUIVALENT DOSES 
Antipsychotics vary greatly in potency and is expressed as differences in 
neuroleptic or chlorpromazine equivalents based on the early dopamine binding 
studies and some on largely by clinical experiences, for first generations and it 
is somewhat inappropriate for second generations due to their usually well 
defined dose-response relationship, though it is still followed in comparative 
studies.  
EQUIVALENT DOSES IN mg/DAY [FOR 100mg OF 
CHLORPROMAZINE/DAY].  
Fluphenazine-2 
Trifluoperazine-5 
Flupentixol-3 
Zuclopenthixol- 5 
Haloperidol  3,  Maudslay guidelines 9th edition.  
Sulpride-200 
Pimozide-2 
Loxapine-10 
Resperidone-2 
Olanzapine-5 
Quetiapine-75 
Ziprazidone-60 
Aripiprazole 7.5 - [J Clin Psychiatry 2003;64;663-7]  
DRUG EMERGENT METABOLIC SYNDROME OBESITY 
Obesity is a chronic illness due to excess body fat by enlargement of fat 
cell size [hypertrophic] or increase in fat cell number [hyper plastic] or both 
and results from greater caloric intake than expenditure.Women typically 
collect fat in gluteofemoral region giving the ‘pear shape’ called gynoid or 
peripheral obesity.Men collects fat usually in the abdomen both subcutaneous 
and visceral region giving the ‘Apple shape’ called android /upper body/central 
obesity which is more associated with CAD health. Obesity is assessed by 
Body Mass Index [BMI]. 
OBESITY AND ANTIPSYCHOTICS 
Weight gain liabilities is to be considered holistically in terms of 
sociodemographics, dietary habits, co morbidities like binge eating, 
hypothyroidism and other medical illnesses likely to be associated to the 
metabolic derangements, patient behaviour like smoking and inactivity, family 
history, premorbid weight status, body composition, psychiatric illnesses and 
treatment factors.A weight gain liability of both first generation and second 
generation was reported based on the meta-analysis of 81 studies in 
schizophrenia  in short time (10 weeks) for clozapine 4kg, olanzapine 3.5kg, 
chlorpromazine 2.1kg, Risperidone 2kg and ziprasidone .04kgmg.- Am J 
Psychiatry 156;1686-96, 1999.   
An increase which is more than 7% of the baseline weight for 
olanzapine 10 times, quitiapine 4 times, risperidone 2 times was reported –
casey et al 2004. The rate is more during the first 2-3 months, but continuous 
effect reported for clozapine even after1 year and 6-9 months for olanzapine 
and some had continuous rise for several years.The pattern of increase is more 
in the form of subcutaneous and intra abdominal fat deposition. – (zhang et al 
2004. 
Weight gain correlation studies.1.Younger age more risk  -Kelly et al 
1998, lane et al 2003. 2.Female more risk - Gopalaswamy and morgan 1985.  
3.Males more risk -  Kinon et al 1998.  4.No sex difference-  -Lane et al 2003.  
5.Ethnicity-non whites more risk - Bassoon et al 2001,lane et al 2003.  
6.Cigarette smoking-no association - Ellingrod et al 2002. 6.Normal or 
underweight more risk- Kinon et al 1998,lane et al 2003. 7.Antipsychotic naive 
more risk-Wetterling and mussigbrodt 1999.  8.Positive association for dose-
Lane et al 2003, nemerof 1997. 9.No association for dose - Ganguly 1999, 
Johnson and breen 1979. 10.Duration of rise -3.3 kg for risperidone after 1 year 
by Amry et al 1997 and  after 2 years- Csernansky et al 1999  11.Positive 
relation with Clinical response  -Bustillo et al 2003,dobmeir et al 2000kinon et 
al 1998. 12.No correlation -Lamberti et al1992,  umbricht et al 1994.  
13.Positive relation with olanzapine and clozapine and no relationship with 
risperidone and haloperidol  -Zang et al 2003.   14.Atypical more than 
conventional   - comprehensive review by ewcomer 2005. 
Obese persons have down regulations of striatal D2 receptors and 
increased feeding behaviour. –wang et al 2001. Serotonin is a satiety factor 
influencing food preferences -De vry and schrieber 2000.Histamine 1,2,3 
receptors play in the regulation of body weight, drinking and feeding behaviour 
with H1 receptor showing high correlation for short term increases. 
GABAnergic medications promote weight gain and glutamate agonists 
stimulate feeding behaviour. Prolactine stimulates food intake, fat deposition, 
and lipolysis and deceases insulin binding and glucose uptake in 
adipocytes.Leptin is an adipocyte-derived peptide that regulates energy intake, 
energy expenditure. Ghrelin is a 28-amino acid orexigenic peptide and is 
inversely associated with energy balance. Patients receiving antipsychotic 
medication frequently report a change in the subjective feeling of fullness and 
satiety, food preferences- (Theisen et al. 2003). Dysregulation of central 
mechanisms (e.g., hypothalamic) also seen. Uncoupling proteins occupy a 
pivotal role in regulating energy expenditure through peripheral mechanisms.     
DIABETES MELLITUS 
 Type I DM- Characterised by no or limited insulin, seen in early life 
and accounts for 5 to 10 percent of all diabetes. It is predominantly T 
cell mediated auto immune process selectively destroys insulin 
producing pancreatic beta cells. 
 Type  II - usually due to insulin resistance, later on insulin deficiency 
may occur. 
 Genetic vulnerability with obesity are common causes, leading to many 
complications like cardiac diseases, stroke, kidney diseases ,peripheral vascular 
diseases, retinopathy, leg ulcers and amputations ,neuropathy, digestive 
diseases and periodontal disease In general, increase in insulin resistance is 
anticipated to occur secondary to increases in adiposity et al. - (Ebenbichler 
2003; Eder et al. 2001). A Significant minority of patients may experience 
glucose dysregulation independent of weight or adiposity differences- Kemner 
et al. 2002; Koller and Doraiswamy 2002;  
The Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) 
study is a major ongoing National Institute of Mental Health-sponsored 
prospective trial designed to assess the efficacy of the second-generation 
antipsychotic agents olanzapine, quetiapine, risperidone, and ziprasidone, with 
perphenazine included as a representative first-generation agent. 1,493 patients 
with schizophrenia at 57 sites in the United States. The primary outcome 
measure is time to all-cause discontinuation. Phase I results were published in 
September 2005. olanzapine group gained more weight than patients in any 
other group (mean weight gain = 2lb per month), and 30% of patients in the 
olanzapine group gained 7% or more of their baseline body weight (vs. 7%-
16% in the other groups; P<0.001). Olanzapine – treated patients also showed 
the greatest increases in total cholesterol (mean increase = 9.7 + 2.1 mg/dl), 
with statistically significant differences between treatment groups in each of 
these indices- (Lieberman et al. 2005). 
DYSLIPIDEMIA 
Induction of hyperlipidemia during antipsychotic therapy thus represents 
a serious condition not only because of its inherent impact on cardiovascular 
risk but also because it is occurring in a group that possesses considerable risk -
(Saari et al. 2004).The atypical antipsychotics have a decreased liability for 
neurological side effects, but have a marked propensity for adverse metabolic 
outcomes, especially hyperlipidemia.- (Meyer and Koro 2004). This is 
bolstered by the recent publication of the double-blind, controlled data from 
Phases I and II of the CATIE Schizophrenia Trial- (Lieberman et al. 2005; 
Stroup et al. 2006).Typical antipsychotics , chlorpromazine and other low-
potency phenothiazines, have greater effects on triglyceride concentrations.- 
(Clark and Johnson 1960; Clark et al. 1967; Mefferd et al. 1958 
HYPERTENSION 
It is a chronic, often symptomless condition defined arbitrarily as 
elevated blood pressure of 140/90 or more, most common form is idiopathic 
causing increased risk of CAHD, CVD and stroke, cardiomyopathy, renal 
failure, peripheral vascular disease 
AETIOLOGY 
 90 percent are idiopathic but genetic and familial influences are seen. 
 Pathophysiologically, activation of sympathetic nervous system and 
rennin angiotensin are important determinants. 
 Transient regulation is by vasoconstriction of the smooth muscle 
media layer of the vessel walls of small arterioles and long term 
regulation is by renal excretion of sodium, potassium and free water. 
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METHODOLOGY 
A COMPARATIVE STUDY BETWEEN FIRST GENERATION AND 
SECOND GENERATION ANTIPSYCHOTICS OVER THE 
DEVELOPMENT OF METABOLIC SYNDROME IN PERSONS WITH 
FIRST EPISODE DRUG NAÏVE SCHIZOPHRENIA 
AIM 
        To compare the first generation and second generation antipsychotics in 
first episode schizophrenia. 
OBJECTIVES 
 To prospectively study the development of metabolic syndrome as 
per the AMERICAN HEART ASSOCIATION [Review of US 
national cholesterol education programme adult treatment panel III-
2001] criteria between first and generation antipsychotics in drug 
naïve first episode schizophrenia. 
 To study the impact of familial and premorbid metabolic profiles 
during the treatment.  
HYPOTHESIS 
Second generation antipsychotics cause more metabolic derangements 
than first generation antipsychotics. 
NULL HYPOTHESIS 
        There is no difference between these two groups over the development of 
metabolic syndrome. 
STUDY DESIGN 
 Prospective 
 Comparative 
 Randomized 
 6 months duration, recruitment period from April 1
st
 to May 15
th
  and the 
data collection was completed in November 15
th
.   
CONSENT APPROVAL 
Apart from history, both patient and informants were explained about 
the details of the study and the informed consent was obtained both from the 
patient and the informants in the prescribed format. The institutional ethical 
committee’s approval was obtained prior to the study and the protocols were 
followed throughout the study. 
STUDY CENTRE 
Outpatient department, Institute mental health,Chennai-10 
MATERIALS AND METHODS 
INCLUTION CRITERIA 
 First episode schizophrenia as per DSM IV-TR. 
 AGE-18 TO 45 yrs. 
 Both sexes 
EXCLUTION CRITERIA 
 Comorbid psychiatric illness. 
 Comorbid substance abuse. 
 Comorbid diabetes mellitus, hypertension, obesity, dyslipidemia. 
 Other medical illness. 
PROCEDURE 
 All new persons attending out- patient department with the diagnosis of 
first episode drug naive schizophrenia as per DSM IV–TR diagnostic criteria 
from April 1
st
 May15th were included. Total number of persons screened was 
67. 11 persons were excluded due to the medical illness and substance abuses. 
2 persons were not willing to enter the study and 1 person preferred to get 
follow-up at the local leval.The total number of individuals selected is 53.They 
were divided in to two groups with 24 in haloperidol and 29 in the risperidone 
by simple random method. Any one drug in first generation or second 
generation group of antipsychotics was used with Chlorpromazine equivalent 
doses of minimum and maximum dose.Anticholinergic and benzoddiazepines 
were used if needed. Drugs were allotted by simple random method by the 
treating clinician. On day one complete psychiatric history along with physical 
examination, baseline assessment of anthropometric measures and rating scales 
was done. Hematological investigations were done within a week. 
INSTRUMENTS USED 
PSYCHOPATHOLOGY 
1 DSM IV-TR  -Diagnostic criteria for schizophrenia. 
2 PANSS [Positive and negative symptoms scale]. 
3 Simpson Angus rating scale. 
METABOLIC ASSESSMENT 
1. AMERICAN HEART ASSOCIATION [Review of US national 
cholesterol education programme adult treatment panel III-2001] criteria 
for metabolic syndrome. 
2. DIABETES MELLITUS Overnight fasting plasma glucose. 
3. HYPERTENTION 10 Minutes after relaxation Sitting posture 3 
recordings at 10 minutes interval of average readings. 
4. OBESITY Height with light clothing in centimeters with standardized 
scale. Weight in kilograms. Waist circumference in centimeters-
measured over the midpoint between the lowest margin of the costal 
cartilage and the highest point of the iliac crest. Hip circumference-at 
the level of the most prominent part of the ischium posteriorly.          
Weight –Hip ratio.  Body Mass Index—weight in kilograms divided by 
meters2. 
LIPID PROFILE 
Triglycerides, High density cholesterol, Total cholesterol after 12 hours 
fasting state. 
ASSESSMENT INTERVAL 
          Baseline - Anthropometric measurements, psychopathological 
assessment by rating scales and blood investigations. 
* Every two months-Laboratory investigations in additions to 
anthropometric measurements. 
DATA COLLECTION 
* SOCIODEMOGRAPHIC DATA 
          Name, age, sex, education, marietal status, occupation, religion, language 
are collected. 
* LIFE STYLE HISTORY 
Sedentary 
Moderate physical work 
Strenuous work 
* FAMILY HISTORY -in first degree relatives. 
 Diabetes 
 Hypertension 
 Dyslipidemia 
 Obesity 
 Lifestyle  
 Medical illness 
 Psychiatric illness 
 Substance use including smoking. 
 Treatment for any of the above conditions. 
ROUTINE PHYSICAL EXAMINATIONS 
 CLINICAL 
 Psychiatric and medical history. 
 General examinations. 
 Systemic examinations. 
 LABORATORY 
 Urinalysis. 
 Basic blood investigations. 
 Other investigations accordingly. 
TESTS USED 
1. Students T test [paired]. 
2. Chi-square test. 
3. General linear model analysis. 
4. Multivariate repeat measures -pillai’s trace, wilk’s lambda, 
Hotelling’s trace, Roy’s largest root. 
5. Adjustment for multiple comparisons; Bonferroni corrections.                         
RESULTS 
The current study is a randomised, prospective, comparative one 
between risperidone and haloperidol.the samples were first episode drug naïve 
schizophrenia, divided into two groups by simple random method. Out of 53 
persons irregular follow up was seen in 2 persons in each group and they were 
excluded in the overall analysis. Risperidone group had 29 patients and 24 
patients in haloperidol.The mean age in risperidone was 30.48(SD-8.761) and 
26.08(SD-6.717).After applying t test for equality of means and Levene’s test 
for equality variances significant differences were found with p value of  
.044(df 50.739).  The majority were female, 66.7% in haloperidol group and 
58.6% in Risperidone group. After applying chi square test no significance 
existed between the groups. (P-0.377). 
The majority of the people were unmarried (64.2%) as against married 
one. It is 62.5% in haloperidol group and 65.5% in risperidone group without 
significant inter group difference. (p-.523). 
Socioeconomic status was classified into lower, middle and upper and 
majority were lower class (58.6%) without significant group differences. 
(p.835). 
LIFE STYLE CHARACTERISTICS 
Most of the persons were sedentary (66%) without significant inter 
group differences (p166). 
POSITIVE FAMILY HISTORY OF METABOLIC CONDITIONS  
18.9% of samples had positive family history without intergroup 
differences(p.074). 
Simpson angus score-no significant group difference (p.638).  
Drug profile of both groups were as follows and there is no much 
difference between both groups after calculating chlorpromazine equivalent 
doses in terms of mg of cumulative risperidone (risperidone 102mg and for 
haloperidol group 84mg). P.451-df.1  
Illness duration was classified into less than one year and more than one 
year. After applying chi square test no significant variation was found between 
both groups.(P.131). 
Baseline parameters without intergroup differences with two tailed t test 
with equal variance assumed and not assumed with 95% CI). 
 
 
DRUG_C
ODE 
N Mean 
Std. 
Deviation 
Std. 
Error 
Mean 
Significance 
(2 tailed) 
Df 
Age 
HPL 24 26.08 6.717 1.371 .049 51 
R 29 30.48 8.761 1.627 .44 50.739 
PANSS 
HPL 24 117.75 30.805 6.288 .759 51 
R 29 120.55 34.547 6.415 .756 50.688 
Height 
HPL 24 160.29 7.086 1.446 .155 51 
R 29 157.21 8.248 1.532 .149 50.914 
Weight 
HPL 24 54.38 7.912 1.615 .569 51 
R 29 55.62 7.853 1.458 .570 49.026 
Waist 
HPL 24 81.69 5.532 1.129 .348 51 
R 29 83.29 6.557 1.218 .340 50.973 
Hip 
HPL 24 91.19 7.109 1.451 .496 51 
R 29 92.41 5.925 1.100 .504 44.866 
BMI 
HPL 24 21.3733 4.07488 .83178 .232 51 
R 29 22.6747 3.75449 .69719 .236 47.437 
HDL 
HPL 24 50.08 4.373 .893 .209 51 
R 29 48.48 4.710 .875 .206 50.289 
Triglyc
erides 
HPL 24 134.12 10.868 2.218 .602 51 
R 29 132.45 12.155 2.257 .599 50.667 
BP_Sys 
HPL 24 111.75 12.386 2.528 .600 51 
R 29 110.00 11.702 2.173 .602 48.010 
BP_DI
A 
HPL 24 71.83 7.889 1.610 .667 50 
R 28 70.71 10.360 1.958 .661 49.366 
Sugar_
FAS 
HPL 24 90.92 5.492 1.121 .512 51 
R 29 89.83 6.359 1.181 .507 50.890 
Sug_pp 
HPL 24 125.75 10.113 2.064 .282 51 
R 29 122.69 10.282 1.909 .282 49.454 
 
At the end of two months the dependentant variables were 
assessed.Increases in  weight, triglycerides, HDL cholesterol, fasting blood 
sugar, body mass index were more prominent with highly significant p 
value(p.002 for HDL, p .018 for PANSS reduction, p .000 for weight, 
triglycerides, blood sugar) 
Between-Subjects Effects-BLOOD PRESSURE 
Source df Sig. 
Intercept 1 .000 
DRUG_CODE 1 .000 
Error 47  
 
There was a significant differences was found in blood pressure of both 
systolic and diastolic with highly significant p value of .000, which is not found 
in anyother parameters. The mean fall is 3.2 systolic and 2.6 in diastolic for 
risperidone, and mean rise of 4 in systolic and 2.1 in diastolic for haloperidol.  
 
At the end of 
four months 
BP_Sys4 
HPL 122.27 15.920 49 .003 
R 110.31 11.361 36.298 .005 
BP_dys4 
HPL 79.36 8.471 49 .004 
R 72.21 8.407 45.183 .004 
 
The same pattern of significant difference as in two months was 
continued in blood pressure changes between risperidone (p .004) and 
haloperidol (.003). 
At the end of six months the inter group differences were more marked 
with p value of .000 for systolic and p value of .004 in risperidone and .005 in 
haloperidol. 
 
 
 BP_sys6 HPL 23 121.22 10.596 2.209 50 .000 
R 29 108.28 11.145 2.070 48.317 .000 
BP_dia6 HPL 24 78.25 7.537 1.538 51 .005 
R 29 71.17 9.614 1.785 50.873 .004 
 
Multi variate analysis was done to compare the marginal means of the 
two groups based on the linearly independent pair wise comparisons with 
pillais trace, wilks lambda,hotellings trace, roys largest root.adustment for 
multiple comparisons were done with bonferroni correction.Al values are with 
95% CI.and p value sfgnificant below .05 
 PAIRWISE COMPARISONS OF PANSS SCORE 
(I) factor (J) factor 
Mean Difference 
(I-J) 
Std. Error Sig.
a
 
1 2 36.324
*
 2.789 .000 
3 66.255
*
 4.019 .000 
4 62.096
*
 3.890 .018 
2 1 -36.324
*
 2.789 .000 
3 29.930
*
 2.595 .000 
4 25.772
*
 2.709 .018 
3 1 -66.255
*
 4.019 .000 
2 -29.930
*
 2.595 .000 
4 -4.158 3.063 1.000 
4 1 -62.096
*
 3.890 .018 
2 -25.772
*
 2.709 .000 
3 4.158 3.063 1.000 
 
  
 
 
 
 
 
 
 
Reduction in PANSS score  is significant from baseline to second 
months and from second month to fourth month.(p .018). Tests of Between-
Subjects Effects The group difference is insignificant.(p.888).  Rapid fall in 
PANSS occurred almost 40 points reduction in first two months. 
WEIGHT GAIN 
All persons in the risperidone  group developed weight gain and  20 
persons (83.3%) in the haloperidol group with highly significant p value of  
.000 and no difference between groups( p value .505). 
PAIRWISE COMPARISONS 
Weight Std. 
Error 
Sig.
a
 
(I) factor (J) factor Mean Difference (I-J) 
1 2 -1.394
*
 .172 .000 
3 -1.981
*
 .294 .000 
4 -2.589
*
 .383 .000 
2 1 1.394
*
 .172 .000 
3 -.586 .249 .137 
4 -1.194
*
 .324 .004 
3 1 1.981
*
 .294 .000 
2 .586 .249 .137 
4 -.608 .278 .203 
4 1 2.589
*
 .383 .000 
2 1.194
*
 .324 .004 
3 .608 .278 .203 
 
Source df Sig. 
Intercept 1 .000 
DRUG_CODE 1 .990 
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The graph shows rapid gain during the first 2 months (p .000)  
BODY MASS INDEX 
Weight gain is more marked in the first two months with a mean of 
1.394 kg and less rise between 2 to 4 months. Tests of Between-Subjects 
Effects show less significant( p .990) 
Significant change occurred as in weight gain with p value of .000 (95% 
CI) during the first two months. 
PAIRWISE COMPARISONS 
BMI-as in weight the most vulnerable period is first two months-p.000. 
(I) 
factor 
(J) 
factor 
Mean Difference 
(I-J) Std. Error Sig.
a
 
1 2 -.561
*
 .069 .000 
 3 -.790
*
 .116 .000 
 4 -.968
*
 .190 .000 
2 1 .561
*
 .069 .000 
 3 -.229 .096 .130 
 4 -.408 .171 .126 
3 1 .790
*
 .116 .000 
 2 .229 .096 .130 
 4 -.179 .141 1.000 
4 1 .968
*
 .190 .000 
 2 .408 .171 .126 
 3 .179 .141 1.000 
Tests of Between-Subjects Effects 
Measure-BMI 
Transformed Variable: Average 
 
Source df 
Intercept 1 
DRUG_CODE 1 
The intergroup difference is insignificant-p 
value is .499 as in the graph 
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More rise in BMI up to 0.65 (P .000)  
 Blood pressure changes are less and it is more in risperidone group with 
p value of p.000 at 95% CI. 
PAIRWISE COMPARISONS 
Measure. Blood pressure 
(I) factor (J) factor Mean Difference (I-J) 
Std. 
Error 
Sig.
a
 
1 2 -.086 1.455 1.000 
 3 -4.555 2.586 .508 
 4 -3.538 1.481 .126 
2 1 .086 1.455 1.000 
 3 -4.469 2.406 .417 
 4 -3.452 1.644 .247 
 
 
 
Source df Sig. 
Intercept 1 .000 
DRUG_CODE 1 .000 
 
 
 
 
 
 
 
 
 
 
 
The initial overall rise is confounded by fall in risperidone group. (p 
.000). 
HDL cholestrol changes occurred in 19 persons(79.9%) in haloperidol 
group and in 26 persons(89.6%) in risperidone group. There are no differences 
between the groups (p .540). 
PAIRWISE COMPARISONS 
Measure:HDL 
 
(I) factor (J) factor 
Mean Difference 
(I-J) Std. Error Sig.
a
 
1 2 3.566
*
 .749 .000 
3 4.534
*
 .797 .000 
4 4.520
*
 .702 .000 
2 1 -3.566
*
 .749 .000 
3 .969
*
 .247 .002 
4 .954
*
 .248 .002 
3 1 -4.534
*
 .797 .000 
2 -.969
*
 .247 .002 
4 -.014 .305 1.000 
4 1 -4.520
*
 .702 .000 
2 -.954
*
 .248 .002 
3 .014 .305 1.000 
 
HDL decrease during the early period is highly significant ( p .002) 
Tests of Between-Subjects Effects 
Source df Sig. 
Intercept 1 .002 
DRUG_CODE 1 .658 
Inter group difference is insignificant. 43  
 
The HDL changes is less from 4
th
 month to 6
th
 month (p.858).  
 
 
 
 
 
 
 
 
 
Hip circumference change seen 21 persons (87.5%) in haloperidol group 
and in all persons in resperidone group .it is more marked from 2
nd
 month to 4
th
 
month (p .000) without group differences. 
PAIRWISE COMPARISONS 
Measure-HIP 
(I) factor (J) factor 
Mean Difference 
(I-J) 
Std. Error Sig.
a
 
1 2 -.395 .386 1.000 
3 -.657 .412 .704 
4 -.447 .442 1.000 
2 1 .395 .386 1.000 
3 -.262 .095 .051 
4 -.053 .184 1.000 
3 1 .657 .412 .704 
2 .262 .095 .051 
4 .209 .200 1.000 
4 1 .447 .442 1.000 
2 .053 .184 1.000 
3 -.209 .200 1.000 
 
Tests of Between-Subjects Effects 
Measure-HIP 
Source df Sig. 
Intercept 1 .000 
DRUG_CODE 1 .561 
There is no inter group differences 48  
 
Hip circumference rise is more up to 4 months (p .000) without inter 
group difference. 
 
 
 
 
 
 
 
 
Increased triglyceride differences were seen in 19 persons (79.1%) and 
25 persons (86.2%)  in risperidone group, which is highly significant during the 
first two months.( p .012). 
PAIRWISE COMPARISONS 
Measure: TRIGLYCERIDES 
(I) 
factor 
(J) factor 
Mean Difference 
(I-J) 
Std. Error Sig.
a
 
1 2 -5.454
*
 1.231 .000 
3 -8.766
*
 2.273 .002 
4 -9.877
*
 1.247 .000 
2 1 5.454
*
 1.231 .000 
3 -3.313 2.116 .750 
4 -4.423
*
 1.337 .012 
3 1 8.766
*
 2.273 .002 
2 3.313 2.116 .750 
4 -1.111 2.004 1.000 
4 1 9.877
*
 1.247 .000 
2 4.423
*
 1.337 .012 
3 1.111 2.004 1.000 
 
Source Df Sig. 
Intercept 1 .000 
DRUG_CODE 1 .652 
Error 42  
 
Inter group difference is insignificant at p .652 
Tests of Between-Subjects Effects 
 
 
 
 
 
 
 
 
As seen in the graph 6 point rise seen in first 2 months (p .000) and less 
rise from 4
th
 to 6
th
 month. 
PLASMA GLUCOSE 
PAIRWISE COMPARISONS 
Blood sugar[f] rise is more in the first two months with p value of .000 
and .003 
Measure-BLOOD SUGAR –fasting 
 
(I) factor1 (J) factor1 Mean Difference (I-J) 
Std. 
Error 
Sig.
a
 
1 
2 -3.799
*
 .999 .003 
3 -6.648
*
 1.495 .000 
4 -6.036
*
 1.028 .000 
2 
1 3.799
*
 .999 .003 
3 -2.849 1.305 .208 
4 -2.237 1.276 .522 
3 
1 6.648
*
 1.495 .000 
2 2.849 1.305 .208 
4 .613 1.414 1.000 
4 
1 6.036
*
 1.028 .000 
2 2.237 1.276 .522 
3 -.613 1.414 1.000 
 
Tests of Between-Subjects Effects 
Measure: Blood sugar 
Transformed Variable: Average 
 
Source df Sig. 
Intercept 1 .000 
DRUG_CODE 1 .587 
No significance between the groups  (p .587). 42  
 
 
 
 
 
 
 
 
 
Fasting sugar value rose up to 7 points in the first 4 months with p value 
of .000 waist circumference increases in waist circumferences were seen  in 21 
persons(87.5%) in haloperidol group and27persons (93.1%) in risperidone 
group with the p value of .005 995% CI). This is more marked during the first 
two months as seen in the graph.  
PAIRWISE COMPARISONS 
Measure: WAIST 
(I) 
factor 
(J) factor 
Mean  Difference 
(I-J) 
Std. Error Sig.
a
 
1 2 -.663 .475 1.000 
3 -.894 .468 .375 
4 -.803 .549 .902 
2 1 .663 .475 1.000 
3 -.231
*
 .068 .008 
4 -.139 .267 1.000 
3 1 .894 .468 .375 
2 .231
*
 .068 .008 
4 .092 .270 1.000 
4 1 .803 .549 .902 
2 .139 .267 1.000 
3 -.092 .270 1.000 
 
Tests of Between-Subjects Effects 
Measure WAIST 
Transformed Variable: Average 
 
Source Df Sig. 
Intercept 1 .000 
DRUG_CODE 1 .246 
Error 46  
 
 
 
 
 
  
DISCUSSION 
Schizophrenia itself is a vulnerable one with at least two fold increased 
risk factor for the development of metabolic syndrome. Treatment with 
antipsychotics unequivocally is associated with  differential liabilities by 
various drugs belonging to both first generation and second generation groups. 
Among the first generation, the phenothiazine group like chlorpromazine has 
more risk than high potency butyrophenones like haloperidol. After the 
introduction of second generation antipsychotics, it was found that they cause 
more metabolic derangements than first generation antipsychotics by various 
studies. Clozapine and olanzapine causes more derangements, risperidone and 
quitiapine to the moderate extent.ziprazidone, aripiprazole has doubtful 
liabilities. The current study is one of few studies done in first episode drug 
naive persons to eliminate the disease effect and very few studies were done in 
these populations. 
At the end of two months in metabolic derangements, there are no 
differences among educational status, marietal states, religion, and 
occupation.Out of 10 persons who developed metabolic syndrome, 7 persons 
had illness duration less than 1 year. sedentary lifestyle pattern was seen in 8 
persons and positive family history of metabolic diseases in 7 persons. Early 
response to anti psychotics with more than 40% reduction as seen in PANSS 
score, was positively associated with weight gain, rise in fasting plasma 
glucose, increases in triglycerides, decreases in HDL cholesterol  significantly( 
p value .002). This pattern was reported earlier by Lane et al 2003. The 
correlation of glucose regulation with rise in body mass index may be 
secondary to adiposity.  -Eder et al 2001. This may contribute to 30 to 40% of 
variance of insulin resistence-Farin et al 2005. At the same time a significant 
population develop insulin resistence independent of it-Koller et al 2003. 
Risperidone had minimal propensity to increase  waist circumference rather 
than  hip circumference  without significant difference between the groups( p 
.202) in overall increases in body mass index.  In both systolic and diastolic 
blood pressure, there was reduction in risperidone group(mean score 9.37) with 
high significant p value of .000 as against rise in haloperidol group(mean rise 
7). This may be explained by the risperidone’s significant action at alpha-2 
adrenergic receptors. No persons met the criteria for metabolic syndrome 
during the first two months. All other parameters of metabolic components 
correlated with the later development of metabolic syndrome as shown in 
earlier studies. 
At  the end of four months, the differences in blood pressure change is 
significant (p.000) between the groups with rise in both groups 7.14 in 
risperidone and 2 in haloperidol and the overall change is insignificant (p .064) 
.Two persons in haloperidol (8.3%) and 3 persons (10.3%) in risperidone group 
developed metabolic syndrome. 
At the end of six months 10 persons (18.86%) developed metabolic 
syndrome as per the US national cholesterol education treatment programme 
(Adult treatment panel III) criteria.  Haloperidol group caused 4 persons 
(16.6%) and risperidone group caused 6 persons (20.6%) with minimal 
increases in the risperidone group, which was found to be statistically 
insignificant.The minimal difference in producing metabolic changes between 
risperidone and haloperidol was shown in various studies like one conducted 
by Saddichsa, Manchunatha, a short term prospective study (6 weeks 
duration).The changes in blood glucose level occurred in 9.1% in risperidone 
and 9.7% in haloperidol group. This study was conducted in Indian population.  
A similar Indian study done by Shiv Gautham,Parth sing Meena in drug naive 
schizophrenia, which is a randomized prospective study done for 4 months 
showed 11.66% metabolic syndrome after 4 months. No patient met criteria for 
metabolic syndrome with haloperidol, with minimal changes and 10% in the 
risperidone group developed metabolic syndrome. A meta-analysis done  by 
Goodnig anbGerry 2002 showed less difference among haloperidol and 
risperidone to produce dyslipidemia. A prospective study in Indian population 
revealed no significant changes in the end among Trifluperazine, haloperidol, 
and olanzapine for BMI and glycemic changes. A similar study by Babes J et al 
in schizophrenia showed weight gain in 30.6% for risperidone and22.4% for 
haloperidol.   
 CONCLUSION 
Antipsychotic drug both risperidone and haloperidol causes significant 
rise in weight, body mass index, plasma glucose, triglycerides, HDL 
cholesterol, hip circumference, waist circumference. Risperidone has slight 
preference to elevate waist circumference rather than hip circumference 
compared with haloperidol. The changes were more marked during the first 
two months. This shows the need for stringent guide lines in antipsychotic 
treatment to prevent the cardiovascular and cerebrovascular morbidity and 
mortality. In contrast to other metabolic derangements, risperidone causes 
reduction in blood pressure changes, more so during the first two months as 
against the gradual rise in haloperidol with the therapeutic implication of 
precaution at the initiation of the drug. The absence of significant difference 
between the two groups show, among the second generations, risperidone may 
be considered as equivalent to haloperidol for changes in metabolic profile 
except reduction in blood pressure, which is most significant disadvantage. The 
blood pressure lowering effect of risperidone is more marked during the earlier 
months with the continuing effect in this study warrants stringent precautions 
to avoid potential complications. 
  
LIMITATIONS 
* Inadequate sample size (24 in haloperidol and 29 in risperidone 
group) may have limitations in the result. 
* The pattern of diet intake,apart from the physical activity has to 
be considered in detail in future studies. 
* The duration of study of 6 months may not be adequate to 
unravel the metabolic derangements. 
  
FUTURE IMPLICATIONS 
* More studies have to be conducted in drug naive persons as there 
are limited ones in this area especially in Indian contexts. 
* Exploration in the pharmacogenomic research is a promising area 
to have the drugs with limited side effects in future. 
* Primary prevention in the form of modification of lifestyle 
pattern has to be emphasized apart from at the secondary and 
tertiary level. 
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ANNEXURE 
1. American heart association- [An update of NCEP III] criteria. (Any 3 of 
 the following 5 items) criteria for metadolicsyndrome. 
 Waist circumference more than 40 inches [102cms] for male and 35 
inches [88cms] for female. 
 TG 150mgs or more [1.7mmol/lit]. 
 HDL 40 or more [1.03mmol/lit] for male and 50 0r more [1.29mmol/lit] 
for female. 
 BP 130/85 or  medication in the past. 
 Fasting plasma glucose of 100mgms% [5.6mmol/lit] or treatment in the 
past. 
Others 
 High ‘C’reactive protein used as marker to predict coronary vascular 
disease in metabolic syndrome and it was recently used as a predictor 
for non-alcoholic fatty liver disease in correlation with serum markers 
that indicated lipid glucose metabolism. 
2. POSITIVE AND NEGATIVE SYNDROME SCALE. [PANSS] 
Positive and negative syndrome scale was developed specifically to 
address the psychometric limitations. It is more comprehensive, strictly 
operationalized and standardized. Assessment is done in four phases 35-45 
minutes clinical interview. (KAY, FISZBEIN, OPLER 1987, AND KAY, 
OPLERLINDENMAYER 1988, 1989]. 
Phase -1. First non directive 5-10 minutes interview to establish rapport. 
Phase 2- semi structured phase lasting for 15-20 minutes to elucidate from the 
non-directive phase, the questions ranging from unspecific to specific, direct 
queries. Phase 3-structured phase lasting for another 5-10 minutes for more 
focused and often with varied and rotated ones during repeated assessment. 
Phase 4-Final directive phase to probe ambivalent, guarded response lasting for 
another 5-10 minutes. 
It contains seven items scores for each positive and negative syndrome, 
16 items for general psychopathology, which is scored on seven point 
severity.1 denotes absence of symptom, 2 minimal or suspected, 3 for clearly 
established and interferes little in day-to-day functioning,4 for moderate level 
occasionally interferes in functioning, 5 for moderately severe, distinctively 
impact but not all consuming, 6 severe for gross pathology requiring 
supervision, 7 extreme drastic interference requiring close supervision. Scores 
are categorised separately and as total scores in terms of raw, percentile and 
range. 
POSITIVE SCALE 
P1  -delusion 
P2  -conceptual disorganization 
P3  -hallucinatory behaviour 
P4  -excitement 
P5  -grandiosity 
P6  -suspiciousness 
P7  -hostility 
Negative scale 
N1 –blunted affect 
N2  -emotional withdrawal 
N3  -poor rapport 
N4  -passive/apathetic social withdrawal 
N5 -difficulty in abstract thinking 
N6  -lack of spontaneity and flow of conversation 
N7  -stereotyped thinking 
General psychopathology scale 
G1  -somatic concern 
G2  -anxiety 
G3  -guilt feeling 
G4  -tension 
G5 -mannerism and posturing 
G6  -depression 
G7  -motor retardation 
G8 -uncooperativeness 
G9  -unusual thought content 
G10  -disorientation 
G11  -poor attention 
G12  -lack of judgement and insight 
G14  -disturbance of volition 
G15  -poor impulse control 
G16  -active social avoidance 
Positive syndrome     -sum of P1through P7 
Negative syndrome   -sum of N1 through N7 
General psychopathology –sum of G1 through G16 
Composite index    -positive syndrome-negative syndrome 
Anergia                   -N1+N2+G7+G10 
Thought disturbance 
Activation 
Paranoid / belligerence  
Depression 
Positive Syndrome - Sum of P1 through P7 
Negative Syndrome - Sum of N1 through N7 
Composite index  - Positive Syndrome minus Negative 
Syndrome 
General Psychopathology  - Sum of G1 though G16 
Anergia -  N1+N2+N7+G10  
Thought disturbance -  P2+P3+P5+G9 
Activation -  P4+P3+P5+G9 
Paranoid / belligerence  -  G1+G2+G3+G6 
3.   SIMPSON ANGUS SCALE (SAS) 
 The Simpson Angus Scale  ( extra pyramidal Side Effects Rating Scale) 
is a 10-item instrument developed by GM Simpson and JW Angus.It measures 
the parkinsonian side effects of rigidity, tremor, akinesia, and salivation. 
 The 10 items are present on a five- point scale (0= complete absence of 
the condition, 4 = presence of the condition of extreme form).  7 items measure 
rigidity and one item (gait) for akinesia.  The global score is obtained by 
adding the total  scores divided by the total number of items.Normal range is 
up to o.3  This is commonly used to find the side effects of antipsychotic 
medications. The  mean correlation coefficients  range from 0.87 for glabellar 
tap to 0.52 for gait. The inter ratter reliability is 0.71 to 0.96 -Friedman JH and 
Factor SA, “Atypical Antipsychotics in the Treatment of Drug- Induced 
Psychosis in Parkinson’s Disease,” Movement Disorder, 2000 15 (2)-201-11. 
1. GAIT  
The patient is examined for his gait, armswing,  general posture. 
0 =  Normal 
1 = Diminution in swing during  walking 
2 = Marked diminution in swing with  rigidity in the arm 
3 = Stiff gait and arms held rigidly before the abdomen 
4 =  shuffling gait with propulsion and retropulsion. 
2. ARM DROPPING  
The patient and the examiner  raise their arms to shoulder height and let 
them fall to their sides. A stout slap is normallyheard and with  Parkinson’s 
syndrome, the arms fall  slowly. 
0 =  Normal with loud slap and rebound  
1 = Slow fall and little rebound  
2 = Fall slowed, no rebound 
3 = Marked slowing, no slap.  
4 = Arms fall as though against resistance.  
3. SHOULDER SHAKING  
The patients arms are bent at a right angle at the elbow and taken one at 
a time. The examiner who grabs one hand also clasps the other around the 
patient’s elbow. The patients upper arm is manipulated to and from and the 
humerus is externally rotated. The degree of resistance scored.  
0 =  Normal  
1 = Slight stiffness.  
2 = Moderate stiffness.  
3 = Marked rigidity.  
4 = Extreme, with almost a frozen shoulder  
4. ELBOW RIGIDITY   
The elbow is separately bent at right angles and are passively extended 
and flexed.The  biceps is observed and palpated and the resistance  is rated  of( 
(cogwheel rigidity is noted separately). 
 
0 =  Normal  
1 = Slight stiffness. 
2 = Moderate stiffnes.  
3 = Marked rigidity. 
4 = Extreme stiffness with almost a frozen shoulder. 
5. FIXATION OF POSITION OR WRIST   
The wrist is held in one hand and then the fingers held by the examiner’s 
other hand with the wrist moved to extension with ulnar and radial deviation.   
0 =  Normal  
1 = Slight stiffness. 
2 = Moderate stiffness.  
3 = Marked rigidity. 
4 = Extreme stiffness with almost a frozen shoulder. 
6. LEG PENDULOUSNESS   
The person sits on a table with  legs hanging down and swinging free. 
The ankle is grasped  and raised to partial extension and  allowed to fall.   
0 = The legs swing freely  
1 = Slight diminution in the swing. 
2 = Moderate resistance.  
3 = Marked resistance.  
4 = Complete absence of swing. 
 7. HEAD DROPPING   
The patient lies on a well-padded  table and the head is raised with the 
hand. The hand is  withdrawn and the head is allowed to drop.Normally , the 
head will drop on the table. The  delay or absence is noted.   
0 =  The head falls  with a good thump. 
1 = Slight slowing in fall. 
2 = Moderate slowing. 
3 = Falls stiffly and slowly  
4 = Head does not reach  table 
8. GLABELLA TAP 
Patient is told to open  eyes and not blink. The glabellar region is tapped 
at a steady, rapid speed. The number of  blinks is observed. 
0 =  0-5 blinks 
1 = 6-10 blinks 
2 = 11-15 blinks   
3 = 16-20 blinks  
4 = 21 and more blinks  
9. TREMOR 
Person is observed first, then examined.  
0 =  Normal  
1 = Mild tremor.  
2 = Tremor occurring spasmodically  
3 = Persistent tremor of one or more limbs 
4 = Whole body tremor  
10. SALIVATION  
This is observed while talking and on opening the mouth. 
0 =  Normal  
1 = Excess salivation on mouth opening. 
2 = When excess salivation causing difficulty in speaking.  
3 = Speaking with difficulty due to  excess salivation. 
4  = Frank drooling. 
4.   DSM IV-TR  - Diagnostic criteria for schizophrenia 
A. characteristic symptoms; two or more of the following, each present 
for a significant period of time during a 1 month period or less if successfully 
treated; 
1. Delusions. 
2 Hallucinaions 
3. Disorganised speech [frequent derailment or incoherence] 
4. Grossly disorganized or catatonic behavior 
5.  Negative symptoms like affective flattening, alogia or avolition. 
Only one criterion A symptom is required if delusions are bizarre or 
hallucination of voice keeping a running commentary or voices conversing 
with each other. 
B.social /occupational functioning-For a significant portion of time one 
or more areas of functioning like work, interpersonal relations or self care are 
markedly below normal or failure of expected development in case of children 
or adolescence. 
C. Duration-continuous signs of disturbance persist for at least 6 
months, including at least one month period of active symptoms or less if 
successfully treated including prodromal or residual period. 
D.schizoaffective/mood disorder exclusion- no major depressive, manic 
or mixed episode concurrently with the active phase symptoms except for a 
brief period. 
E.substance /general medical condition exclusion-the disturbance is not 
due to direct effect of general medical condition or substance abuse. 
F.pervasive development disorder-additional diagnosis of schizophrenia 
is made if there are prominent delusions or hallucinations for at least one 
month if there is history of pervasive developmental disorders. 
5. SCREENING PROFORMA 
Case number               Enrolment     Date 
Address 
Informants 
Identity marks 
Date of visits 
Educational status 
Occupation 
Marietal status 
Religion 
Language spoken 
Socio-economic status-Low/Middle/High 
Life style- sedentary/Active work/Strenuous work 
Family history of first degree relatives 
 Psychiatric disorder. 
 Substance abuse/dependence. 
 Chronic medical illness. 
 Diabetes mellitus. 
 Systemic hypertension. 
 Dyslipidemia. 
 Obesity 
 Base 
line 
Two 
months 
Four 
month 
Six 
months 
 PANSS score  
 Simpson 
           Angus score 
 Height 
 Weight 
 Waist circumference 
 Hip circumference 
 Body Mass Index 
 Blood sugar fasting and 
post prandial 
 Blood pressure 
 Triglycerides 
 HDL cholesterol 
 Drug name 
 Drug dose 
 Adverse reactions if 
any 
 
    
                                                                                                       
 
A COMPARATIVE STUDY BETWEEN FIRST GENERATION AND 
SECOND GENERATION ANTIPSYCHOTICS OVER THE 
DEVELOPMENT OF METABOLIC SYNDROME IN FIRST 
EPISODE DRUG NAIVE PERSONS WITH SCHIZOPHRENIA. 
  Introduction   Metabolic syndrome denotes a constellation glycemic 
dysregulation, hypertension, dyslipidemia, elevated body 
mass index producing    hypercoagulable and proinflmmatory 
state. Antipsychotics especially, second generation drugs 
cause more derangements. It occurs in schizophrenia which 
itself is a vulnerable factor. 
  Aim To compare the development of metabolic syndrome 
between these groups in drug naive first episode 
schizophrenia. 
  Method This is a randomized, prospective one .Risperdone had 29 
and haloperidol 24 persons.They were assessed at baseline, 
second, fourth and six months. 
  Result  Significant changes [p.000] occurred in elevation of body 
mass index, serum triglycerides, plasma glucose, and HDL 
cholesterol. This correlated with reduction in PANSS score, 
more so in the first two months, without significant inter 
group differences statistically. The risperidone group caused 
significant reduction in both systolic and diastolic blood 
pressure (p .006)  as against gradual rise in haloperidol 
group, more marked in first two months. 
  Discussion The current study is one of very few studies done in drug 
naive first episode. over all 18.86%  developed metabolic 
syndrome according to American heart association criteria, 
20.6%  in risperidone and 16.6%  in haloperidol  without 
significance statistically.This pattern of moderate potential of 
risperidone among second generation antipsychotics and the 
relatively low incidence of high potent haloperidol were 
shown in various studies.Risperidone’s reduction reveals the 
therapeutic implication of stringent precaution on initiation of 
therapy.These inferences may be replicated in future with 
more samples and longer duration.   
